4WM
GTBP icon

49 Wealth Management’s GT Biopharma GTBP Stock Holding History

49 Wealth Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$31.3K Buy
+2,560
New +$26K 0.01% 189

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

49 Wealth Management's GTBP Position: Q2 2026 in Review

49 Wealth Management opened a new position in GT Biopharma (GTBP) in Q2 2026: 2,560 shares worth $31.3K. The stake represents 0.01% of the portfolio and ranks #189 among its holdings.

55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • 49 Wealth Management held 2,560 shares of GT Biopharma worth $31.3K as of Q2 2026.
  • GT Biopharma was a new 49 Wealth Management position in Q2 2026.
  • GT Biopharma made up 0.01% of 49 Wealth Management's portfolio in Q2 2026, its #189 holding.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on 49 Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.